Government of Canada. Opioid—and Stimulant-Related Harms in Canada. Ottawa, Ontario: Government of Canada. 2022.
Centers for Disease Control and Prevention (CDC). Drug overdose: death rate maps and graphs. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. 2022.
Ahmad FB RL, Sutton P. Provisional drug overdose death counts. National Vital Statistics System, National Center for Health Statistics, Centres for Disease Control and Prevention (CDC). 2022.
Jones CM, Houry D, Han B, Baldwin G, Vivolo-Kantor A, Compton WM. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction. Ann N Y Acad Sci. 2022;1508(1):3–22.
Article CAS PubMed Google Scholar
Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among us adults. JAMA Psychiat. 2021;78(12):1329–42.
Jones CM, Compton WM, Mustaquim D. Patterns and characteristics of methamphetamine use among adults—United States, 2015–2018. MMWR Morb Mortal Wkly Rep. 2020;69(12):317–23.
Article PubMed PubMed Central Google Scholar
Canadian Centre for Substance Use and Addiction (CCSA). Canadian Drug Summary: Methamphetamine. Ottawa, Ontario: Canadian Centre for Substance Use and Addiction (CCSA). 2020.
Jones CM, Underwood N, Compton WM. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–17. Addiction. 2020;115(2):347–53.
Jones CM, Han B, Seth P, Baldwin G, Compton WM. Increases in methamphetamine injection among treatment admissions in the US. Addict Behav. 2023;136: 107492.
Palamar JJ, Han BH, Keyes KM. Trends in characteristics of individuals who use methamphetamine in the United States, 2015–2018. Drug Alcohol Depend. 2020;213: 108089.
Article CAS PubMed PubMed Central Google Scholar
Strickland JC, Stoops WW, Dunn KE, Smith KE, Havens JR. The continued rise of methamphetamine use among people who use heroin in the United States. Drug Alcohol Depend. 2021;225: 108750.
Article PubMed PubMed Central Google Scholar
Strickland JC, Havens JR, Stoops WW. A nationally representative analysis of “twin epidemics”: Rising rates of methamphetamine use among persons who use opioids. Drug Alcohol Depend. 2019;204: 107592.
Article PubMed PubMed Central Google Scholar
Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14–20.
Jones CM, Olsen EO, O’Donnell J, Mustaquim D. Resurgent methamphetamine use at treatment admission in the United States, 2008–2017. Am J Public Health. 2020;110(4):509–16.
Article PubMed PubMed Central Google Scholar
Tardelli VS, Johnstone S, Xu B, et al. Trends in emergency department visits and inpatient admissions related to methamphetamines in Toronto, Canada, 2014–2021. Canadian J Psychiatry. 2022. https://doi.org/10.1177/07067437221125302.
Papamihali K, Collins D, Karamouzian M, Purssell R, Graham B, Buxton J. Crystal methamphetamine use in British Columbia, Canada: A cross-sectional study of people who access harm reduction services. PLoS ONE. 2021;16(5): e0252090.
Article CAS PubMed PubMed Central Google Scholar
Lopez AM, Dhatt Z, Howe M, et al. Co-use of methamphetamine and opioids among people in treatment in Oregon: a qualitative examination of interrelated structural, community, and individual-level factors. Int J Drug Policy. 2021;91: 103098.
Article PubMed PubMed Central Google Scholar
Silverstein SM, Daniulaityte R, Getz K, Zule W. “It’s crazy what meth can help you do”: lay beliefs, practices, and experiences of using methamphetamine to self-treat symptoms of opioid withdrawal. Subst Use Misuse. 2021;56(11):1687–96.
Hansen ER, Carvalho S, McDonald M, Havens JR. A qualitative examination of recent increases in methamphetamine use in a cohort of rural people who use drugs. Drug Alcohol Depend. 2021;229: 109145.
Article PubMed PubMed Central Google Scholar
Palmer A, Scott N, Dietze P, Higgs P. Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: a qualitative study. Harm Reduct J. 2020;17(1):14.
Article PubMed PubMed Central Google Scholar
Strang J, Volkow ND, Degenhardt L, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3.
Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. The Lancet. 2019;393(10182):1760–72.
Socías ME, Dong H, Wood E, et al. Trajectories of retention in opioid agonist therapy in a Canadian setting. Int J Drug Policy. 2020;77: 102696.
Article PubMed PubMed Central Google Scholar
Socías ME, Wood E, Kerr T, et al. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006–2016. Drug Alcohol Depend. 2018;189:90–5.
Article PubMed PubMed Central Google Scholar
Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35.
Kurz M, Min JE, Dale LM, Nosyk B. Assessing the determinants of completing OAT induction and long-term retention: a population-based study in British Columbia. Canada J Subst Abuse Treat. 2022;133: 108647.
Article CAS PubMed Google Scholar
Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O’Grady KE, Schwartz RP. Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19(6):35.
Article PubMed PubMed Central Google Scholar
Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. “It’s like ‘liquid handcuffs”: the effects of take-home dosing policies on methadone maintenance treatment (MMT) patients’ lives. Harm Reduct J. 2021;18(1):88.
Article PubMed PubMed Central Google Scholar
Nosyk B, Marsh DC, Sun H, Schechter MT, Anis AH. Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996–2006. J Subst Abuse Treat. 2010;39(1):22–31.
Peles E, Linzy S, Kreek MJ, Adelson M. One-year and cumulative retention as predictors of success in methadone maintenance treatment: a comparison of two clinics in the United States and Israel. J Addict Dis. 2008;27(4):11–25.
Saloner B, Whitley P, Dawson E, Passik S, Gordon AJ, Stein BD. Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety. Addiction. 2023. https://doi.org/10.1111/add.16180.
Frost MC, Lampert H, Tsui JI, Iles-Shih MD, Williams EC. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review. Addict Sci Clin Pract. 2021;16(1):1–25.
Krawczyk N, Williams AR, Saloner B, Cerdá M. Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. J Subst Abuse Treat. 2021;126: 108329.
Article CAS PubMed PubMed Central Google Scholar
Mackay L, Bach P, Milloy M, Cui Z, Kerr T, Hayashi K. The relationship between crystal methamphetamine use and methadone retention in a prospective cohort of people who use drugs. Drug Alcohol Depend. 2021;225: 108844.
Article CAS PubMed PubMed Central Google Scholar
Tsui JI, Mayfield J, Speaker EC, et al. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. J Subst Abuse Treat. 2020;109:80–5.
Pilarinos A, Kwa Y, Joe R, et al. Methadone maintenance treatment discontinuation among young people who use opioids in Vancouver. Canada Can J Psychiatry. 2023;68(2):89–100.
Lo A, Kerr T, Hayashi K, et al. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs. J Subst Abuse Treat. 2018;94:41–6.
Article PubMed PubMed Central Google Scholar
Liu D, Gu J, Xu H, et al. Club drugs and alcohol abuse predicted dropout and poor adherence among methadone maintenance treatment patients in Guangzhou. China AIDS care. 2017;29(4):458–63.
Vafaeinasab MR, Farahzadi MH, Razaghi OM, Fallahzadeh RA, Lotfi MH, Akhondzadeh S. Investigation of affecting factors on persistence in the treatment of patients under methadone maintenance therapy in addiction therapy centers, Yazd-Iran. Health. 2015;7(05):606.
Banta-Green CJ, Maynard C, Koepsell TD, Wells EA, Donovan DM. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users. Addiction. 2009;104(5):775–83.
Gryczynski J, Mitchell SG, Jaffe JH, O’Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients’ reasons for cessation of care. J Subst Abuse Treat. 2014;46(3):356–61.
Comments (0)